Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Singulair Switch NDA Limits Indication To Allergies, Omits Asthma

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will try to convince an FDA advisory committee May 2 to partially switch its blockbuster Rx drug Singulair to OTC for allergy relief in adults only. The firm will not seek to switch the Rx indications for asthma or allergy relief in children.


Related Content

DTC Spending During Rx Life Yields OTC Switch Market Share
Merck Reaffirms Commitment To Consumer Care In Restructuring
Oxytrol For Women Gets OTC Green Light As Rare First-In-Class Switch
Rescue Medicine Switch Concept Draws Criticism
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Martek/Mead Agreement


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts